Loading
Cancer Cells and Metastasis / Immune Cells in Cancer · Journal article
Molecular Therapy — Nucleic Acids · August 14, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of macrophage engineering approaches in cancer, including TAM reprogramming, CAR-Ms, and related genetic modification strategies. It synthesizes mechanistic design principles and candidate interventions but reports no primary empirical results, clinical outcomes, or comparative efficacy data. The work frames future research directions rather than providing evidence of clinical benefit or technical proof-of-concept in a defined population.
Narrative review.
TAM depletion and monocyte recruitment blockade showed limited efficacy; functional reprogramming is proposed as an alternative strategy. Recent advances in viral vectors, CRISPR-Cas, and RNA-delivery platforms enable precise macrophage genetic modification. Effective engineered macrophage function requires stabilization of pro-inflammatory identity, resistance to tumor repolarization, metabolic reinforcement, and checkpoint modulation integration.
Generalizability to human malignancies and in vivo safety or efficacy unknown; review is largely preclinical and conceptual.
The source did not state who this applies to in practice.
This is a narrative review synthesizing mechanistic concepts and engineering strategies in preclinical macrophage biology, raising questions about feasibility rather than reporting clinical or definitive translational evidence.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Macrophages are central regulators of the tumor microenvironment (TME), shaping immune suppression, angiogenesis, metabolism, and therapeutic resistance in solid cancers. While early strategies sought to deplete tumor-associated macrophages (TAMs) or block monocyte recruitment, limited efficacy and compensatory mechanisms revealed the need for functional reprogramming rather than elimination. Recent advances in viral vectors, CRISPR-Cas genome editing, and RNA-based delivery platforms have enabled precise genetic modification of macrophages, giving rise to chimeric antigen receptor macrophages (CAR-Ms) and related engineered products. Beyond antigen targeting, effective macrophage engineering requires stabilization of pro-inflammatory identity, resistance to tumor-induced repolarization, metabolic reinforcement, and integration of checkpoint modulation pathways. This review synthesizes current strategies across DNA, mRNA, and siRNA-based platforms, highlighting convergent design principles that connect TAM reprogramming with CAR-M development. We discuss reshaping phagocytosis checkpoints, metabolic and transcriptional stabilization, cytokine augmentation, and synthetic receptor architecture, emphasizing combinatorial and context-aware engineering, while proposing new candidate gene targets. Engineered macrophages are thus evolving from simple effector cells into programmable immune coordinators capable of converting immunologically “cold” tumors into inflamed, therapy-responsive niches.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.